Molecular Biosystems Inc. of San Diego announced Tuesday thatthe Radiological Devices Advisory Panel of the FDA voted torecommend approval of its Albunex for ultrasound of the heart.
The approval is subject only to minor changes in labelling andinserts and post-marketing surveillance of patients in whichAlbunex is used.
The company's stock (NYSE:MB) closed up $3.25 a share at $27on Tuesday after gaining $2.13 on Monday. The stock hastraded at a 52-week range of $20.50 to 40.88.
(c) 1997 American Health Consultants. All rights reserved.